more frequent side effects
vomiting
comprehensive list of adverse effects
drug
changes in renal
hematological function test results
hepatic abnormalities
therapy with this
comparative agents in some patients
serious underlying diseases
aids
cancer
clinical significance
relationship
therapy
clinical trials of single-dose therapy
side effects
therapy
patients
drug
patients
using active comparative agents
common side effects
patients
single mg dose of this drug for vaginitis
headache
nausea
abdominal pain
most side effects
moderate severity
clinical trials of multiple-dose therapy
side effects
patients
therapy discontinuation
patients
adverse clinical events
laboratory test abnormalities
clinical side effects
hiv-infected patients
non-hiv-infected patients
patterns in both groups
rare cases of seizures
causal relationship
patients
cryptococcal meningitis
severe underlying disease
least case of seizure
mg
oral dose
seizures
dizziness
paresthesia
somnolence
tremor
vertigo
postmarketing experience
headache
seizures
dizziness
paresthesia
somnolence
vertigo
visual field defect
taste perversion
hyperkinesia
hypertoniarare
tremorfrequency
dysesthesias
nausea
abdominal pain
diarrhea
vomitingcommon
dyspepsiauncommon
constipation
flatulence
loose stools
dry mouthfrequency
general
abdominal discomfort
dry mouth
dyspepsia
vomiting
postmarketing experience
fatal hepatic reactions
patients with serious underlying medical conditions
aids
malignancy
taking
taking multiple concomitant medications
patient with aids
acute hepatic necrosis
hepatic failure about weeks
starting
drug
transient hepatic reactions
patients with no other identifiable risk factors
liver function
baseline
stopping
drug
serum transaminase elevations
times
upper limit of normal
uln
significant increases in ast
serum transaminase elevations
patients with serious underlying medical conditions
aids
malignancy
taking
taking multiple concomitant medications
including agents
transaminase elevations
uln
cholestasis
hepatocellular damage
hepatocellular necrosis
postmarketing experience
increased alt
astuncommon
serum transaminase elevations
cholestasis
jaundice
bilirubinrare
serious hepatic reactions
hepatic toxicity
including fatalities
hepatic failure
hepatocellular necrosis
hepatitis
hepatocellular damagefrequency
hepatic reactions
ranging from mild transient transaminase elevations
clinical hepatitis
fulminant hepatic failure
including fatalities
transient hepatic reactions
including hepatitis
jaundice
elevated liver function tests
cholestatic jaundice
fatal hepatic necrosis
increased plasma levels of hepatic enzymes
reversible alopecia
months
therapy
patients with serious underlying diseases
aids
malignancy
exfoliative skin disorders
fatal outcome
acute generalized exanthematous pustulosis
drug eruption
sweating
exfoliative skin disorders
including
stevens-johnson syndrome
toxic epidermal necrolysis
alopecia
postmarketing experience
rashcommon
maculopapular erythemauncommon
pruritus
genital pruritus
erythematous rash
dry skin
abnormal skin odor
urticaria
herpes simplex
drug eruption
sweatingrare
angioedema
exfoliative skin disorders
including
stevens-johnson syndrome
toxic epidermal necrolysis
alopecia
acute generalized exanthematous pustulosis
exfoliative dermatitisfrequency
reversible alopecia
exfoliative skin disorders
including fatalities
increased blood alkaline phosphataseuncommon
hypokalemia
anorexia
appetiterare
hypercholesterolemia
hypertriglyceridemia
hypercholesterolemia
hypertriglyceridemia
hypokalemia
postmarketing experience
rare cases of exfoliative dermatitis
ulcerative eruptions
stevens-johnson syndrome
association with hypersensitivity reactions
fixed drug eruption
fde
single mg
oral dose for extensive pityriasis versicolor
hours
pigmented patches
trunk with diameters
cm
erythematous halos
clinical diagnosis of fde
drug therapy
fde
patient
mg
oral dose
anaphylactic reaction
anaphylaxisfrequency
hypersensitivity reactions
including
generalized edema
stridor
hypotension
exfoliative dermatitis
ulcerative eruptions
fixed drug eruptionpostmarketing reports
anaphylaxis
including angioedema
face edema
pruritus
most reports of qt interval prolongation
torsades de pointes
ill patients with multiple confounding risk factors
structural heart disease
electrolyte abnormalities
concomitant medications
year-old male with neurofibromatosis
hospital in septic shock
perforated gastric volvulus
initial stabilization
patient
total gastrectomy
multiple peritoneal lavages
culture of peritoneal fluid
infection with candida albicans
therapy
fluconazole
active ingredient
diflucan
mg
hours
starting
drug
patient
qt prolongation
complex
ventricular arrhythmia
drug
hours
patient
sinus rhythm
brief run of ventricular bigeminy
ecg
months after admission
months after cessation of all qt-prolonging medications
sinus rhythm with normal heart rate
corrected qt interval
qt prolongation
torsade de pointes
postmarketing experience
qt prolongation
torsade de pointesfrequency
prolongation of the qt interval on the ecg
palpitations
complex ventricular arrhythmia
anemia
eosinophilia
leukopenia
neutropenia
thrombocytopenia
patients with severe deep fungal infections
underlying disease
spontaneous reports of anemia
patients years of age
years of age
natural increase in the incidence of anemia in the elderly
causal relationship
drug exposure
anemia
leukopenia
neutropenia
agranulocytosis
thrombocytopenia
postmarketing experience
anemiarare
leukopenia
neutropenia
agranulocytosis
thrombocytopeniafrequency
eosinophilia
thirst
fatigue
malaise
pain
rigors
asthenia
fever
flushing
hot flushesrare
face edemafrequency
infection
resistant microorganisms
fever
asthenia
fatigue
malaise
postmarketing experience
pain
myalgiafrequency
joint pain
finger stiffness
myalgia
postmarketing experience
insomnia
nervousness
insomnia
postmarketing experience
polyuria
renal pain
changes in renal function testsfrequency
membranous nephropathypostmarketing reports
acute renal failure
history of hypertension
cervical cancer
membranous nephropathy
drug
patient
increasing
increasing generalized edema
nausea
indigestion for weeks
clinical findings
patient
stage
membranous nephropathy
initial presentation
patient
medication history
amlodipine
hydrochlorothiazide
metoclopramide
levosulpiride
taking fluconazole
months after the initial presentation
patient
reports
increasing pedal edema
point
patient
taking
drug
week for tinea pedis
patient
complete remission
drug
spontaneous reports of acute renal failure
patients years of age
years of age
natural increase in the incidence of renal failure in the elderly
causal relationship
drug exposure
intermenstrual bleeding
dysmenorrhea
leukorrhea
menorrhagia
uterine spasm
vaginal disorders
female sexual dysfunction
pharyngitisfrequency
respiratory disorders
abnormal vision
intravenous solution
stomach pain
chills
clay-colored stools
cough
dark urine
diarrhea
difficulty with swallowing
dizziness
fast heartbeat
fever
general feeling of tiredness
weakness
headache
hives
itching
skin rash
hive-like swelling on the face
eyelids
lips
tongue
throat
hands
legs
feet
sex organs
light-colored stools
loss of appetite
nausea and vomiting
puffiness
swelling of the eyelids
eyes
face
lips
tongue
stomach pain, continuing
tightness in the chest
unpleasant breath odor
unusual tiredness
weakness
stomach pain
vomiting of blood
yellow eyes
skin
black, tarry stools
blistering
peeling
loosening of the skin
chest pain
discomfort
convulsions
decreased urine
dry mouth
fainting
hoarseness
increased thirst
slow heart rate
muscle pain
loss of bladder control
side pain
mood changes
muscle pain
cramps
muscle spasm
jerking of all extremities
numbness
tingling in the hands
feet
lips
difficult urination
pale skin
red skin lesions
purple center
red, irritated eyes
sore throat
sores
ulcers
white spots in the mouth
lips
sudden loss of consciousness
swollen glands
unusual bleeding
bruising
fearfulness
suspiciousness
other mental changes
seeing
hearing
feeling things
acid
sour stomach
belching
change in taste
taste
heartburn
indigestion
stomach discomfort
upset
hair loss
thinning of the hair